Deals
Fresenius Says It's in Talks to Buy Generic Drugmaker Akorn
- Companies are in talks, but no final decisions have been made
- Akorn closed up 18 percent after Bloomberg report on talks
This article is for subscribers only.
Fresenius SE, Europe’s biggest publicly traded health-care provider, said Friday that it’s in talks to buy U.S. generic drugmaker Akorn Inc.
While discussions are under way, there’s no certainty of a deal, said Fresenius, a maker of dialysis and medical products. The Bad Homburg, Germany-based company didn’t elaborate in a statement about the talks. A spokeswoman for Akorn declined to comment.